Cargando…

New Biomarkers Based on Dendritic Cells for Breast Cancer Treatment and Prognosis Diagnosis

Dendritic cells(DCs) play a protective role in the antitumor immunity of most cancers, which can be divided into conventional dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs). Most current studies are only based on either cDCs or pDCs for the study of the relationship between DCs and b...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Fanjia, Yan, Fang, Liu, Haihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963148/
https://www.ncbi.nlm.nih.gov/pubmed/36835467
http://dx.doi.org/10.3390/ijms24044058
_version_ 1784896180807794688
author Zhao, Fanjia
Yan, Fang
Liu, Haihong
author_facet Zhao, Fanjia
Yan, Fang
Liu, Haihong
author_sort Zhao, Fanjia
collection PubMed
description Dendritic cells(DCs) play a protective role in the antitumor immunity of most cancers, which can be divided into conventional dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs). Most current studies are only based on either cDCs or pDCs for the study of the relationship between DCs and breast cancer prognosis, without combining the two together. We aimed to select new biomarkers from pDCs and cDCs. In this paper, the xCell algorithm was first used to calculate the cellular abundance of 64 types of immune cells and stromal cells in tumor samples from the TCGA database, and the high-abundance pDC group and cDC group were divided according to the results of a survival analysis. Then, we looked for the co-expressed gene module of highly infiltrating pDC and cDC patients with a weighted correlation network analysis (WGCNA) and screened out the hub genes, including RBBP5, HNRNPU, PEX19, TPR, and BCL9. Finally, we analyzed the biological functions of the hub genes, and the results showed that RBBP5, TPR, and BCL9 were significantly related to the immune cells and prognosis of patients, and RBBP5 and BCL9 were involved in responding to TCF-related instructions of the Wnt pathway. In addition, we also evaluated the response of pDCs and cDCs with different abundances to chemotherapy, and the results showed that the higher the abundance of pDCs and cDCs, the higher their sensitivity to drugs. This paper revealed new biomarkers related to DCs—among them, BCL9, TPR, and RBBP5 were proven to be closely related to dendritic cells in cancer. For the first time, this paper puts forward that HNRNPU and PEX19 are related to the prognosis of dendritic cells in cancer, which also provides new possibilities for finding new targets for breast cancer immunotherapy.
format Online
Article
Text
id pubmed-9963148
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99631482023-02-26 New Biomarkers Based on Dendritic Cells for Breast Cancer Treatment and Prognosis Diagnosis Zhao, Fanjia Yan, Fang Liu, Haihong Int J Mol Sci Article Dendritic cells(DCs) play a protective role in the antitumor immunity of most cancers, which can be divided into conventional dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs). Most current studies are only based on either cDCs or pDCs for the study of the relationship between DCs and breast cancer prognosis, without combining the two together. We aimed to select new biomarkers from pDCs and cDCs. In this paper, the xCell algorithm was first used to calculate the cellular abundance of 64 types of immune cells and stromal cells in tumor samples from the TCGA database, and the high-abundance pDC group and cDC group were divided according to the results of a survival analysis. Then, we looked for the co-expressed gene module of highly infiltrating pDC and cDC patients with a weighted correlation network analysis (WGCNA) and screened out the hub genes, including RBBP5, HNRNPU, PEX19, TPR, and BCL9. Finally, we analyzed the biological functions of the hub genes, and the results showed that RBBP5, TPR, and BCL9 were significantly related to the immune cells and prognosis of patients, and RBBP5 and BCL9 were involved in responding to TCF-related instructions of the Wnt pathway. In addition, we also evaluated the response of pDCs and cDCs with different abundances to chemotherapy, and the results showed that the higher the abundance of pDCs and cDCs, the higher their sensitivity to drugs. This paper revealed new biomarkers related to DCs—among them, BCL9, TPR, and RBBP5 were proven to be closely related to dendritic cells in cancer. For the first time, this paper puts forward that HNRNPU and PEX19 are related to the prognosis of dendritic cells in cancer, which also provides new possibilities for finding new targets for breast cancer immunotherapy. MDPI 2023-02-17 /pmc/articles/PMC9963148/ /pubmed/36835467 http://dx.doi.org/10.3390/ijms24044058 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhao, Fanjia
Yan, Fang
Liu, Haihong
New Biomarkers Based on Dendritic Cells for Breast Cancer Treatment and Prognosis Diagnosis
title New Biomarkers Based on Dendritic Cells for Breast Cancer Treatment and Prognosis Diagnosis
title_full New Biomarkers Based on Dendritic Cells for Breast Cancer Treatment and Prognosis Diagnosis
title_fullStr New Biomarkers Based on Dendritic Cells for Breast Cancer Treatment and Prognosis Diagnosis
title_full_unstemmed New Biomarkers Based on Dendritic Cells for Breast Cancer Treatment and Prognosis Diagnosis
title_short New Biomarkers Based on Dendritic Cells for Breast Cancer Treatment and Prognosis Diagnosis
title_sort new biomarkers based on dendritic cells for breast cancer treatment and prognosis diagnosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963148/
https://www.ncbi.nlm.nih.gov/pubmed/36835467
http://dx.doi.org/10.3390/ijms24044058
work_keys_str_mv AT zhaofanjia newbiomarkersbasedondendriticcellsforbreastcancertreatmentandprognosisdiagnosis
AT yanfang newbiomarkersbasedondendriticcellsforbreastcancertreatmentandprognosisdiagnosis
AT liuhaihong newbiomarkersbasedondendriticcellsforbreastcancertreatmentandprognosisdiagnosis